May 18 (UPI) -- Researchers found that combining a new FDA-approved drug with existing treatment may help treat a rare immunologic disease.
The study by the National Institutes of Health added the injectable drug mepolizumab to the standard treatment for eosinophilic granulomatosis with polyanglitis, or EGPA, a rare immunologic disease.